Literature DB >> 9198237

Angiogenesis: a dynamic balance of stimulators and inhibitors.

M L Iruela-Arispe1, H F Dvorak.   

Abstract

Angiogenesis, the formation of new blood vessels from a pre-existing vasculature, is tightly regulated in normal adults. Under physiological circumstances, angiogenesis occurs in only a few instances; e.g., the female reproductive system in response to ovulation or gestation, the normal hair cycle, etc. In these examples, growth of new capillaries is tightly controlled by an interplay of growth regulatory proteins which act either to stimulate or to inhibit blood vessel growth. Normally, the balance between these forces is tipped in favor of inhibition and consequently capillary growth is restrained. Under certain pathological circumstances, however, local inhibitory controls are unable to restrain the increased activity of angiogenic inducers. Thus, in wound healing, inflammation and tumors, to name just a few examples, angiogenesis is integral to the pathology, engendering the hope that these pathological entities could be regulated by pharmacological and/or genetic suppression (or enhancement) of blood vessel growth. This hope, in turn, has fostered interest in the molecular mechanisms that regulate angiogenesis. In this chapter, we have reviewed the current literature regarding some angiogenic stimulators and inhibitors, emphasizing vascular permeability factor (VPF, also known as vascular endothelial growth factor or VEGF), as a major angiogenic inducer, and thrombospondin (TSP) as the best known example of a natural inhibitor of vessel growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9198237

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  70 in total

Review 1.  Therapeutic angiogenesis.

Authors:  T D Henry
Journal:  BMJ       Date:  1999-06-05

2.  In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis.

Authors:  S M Smorenburg; R Vink; M te Lintelo; W Tigchelaar; A Maas; H R Büller; C J van Noorden
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

3.  Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis.

Authors:  John R Basile; Rogerio M Castilho; Vanessa P Williams; J Silvio Gutkind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

4.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis.

Authors:  P Nangia-Makker; Y Honjo; R Sarvis; S Akahani; V Hogan; K J Pienta; A Raz
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 5.  Radionuclide reporter gene imaging for cardiac gene therapy.

Authors:  Masayuki Inubushi; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

6.  MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1.

Authors:  Aránzazu Chamorro-Jorganes; Elisa Araldi; Luiz O F Penalva; Devraj Sandhu; Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

7.  Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.

Authors:  E M Paleolog; R A Fava
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  Role of growth factors and the wound healing response in age-related macular degeneration.

Authors:  Reinier O Schlingemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-18       Impact factor: 3.117

9.  Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.

Authors:  Eva Ruiz; Carmen Alemán; José Alegre; Jasone Monasterio; Rosa Ma Segura; Lluis Armadans; Ana Vázquez; Teresa Soriano; Tomás Fernández de Sevilla
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

10.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Authors:  Beverly A Teicher; Krishna Menon; Enrique Alvarez; Chuan Shih; Margaret M Faul
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.